This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

AstraZeneca-Icosavax deal may prompt queries from US FTC, but strong rivals, distinct customers could temper concerns

By Ilana Kowarski ( January 26, 2024, 20:28 GMT | Comment) -- Both AstraZeneca and clinical-stage vaccine developer Icosavax offer an immunization for respiratory syncytial virus in their drug portfolio – a similarity that may prompt scrutiny from the US Federal Trade Commission about their $1.1 billion deal. But the parties could argue that with strong rivalry in the RSV inoculation sector and their targeting of different RSV patient populations, the transaction poses little risk to competition. Both AstraZeneca and clinical-stage vaccine developer Icosavax offer an immunization for respiratory syncytial virus (RSV) in their drug portfolio – a similarity that may prompt scrutiny from the US Federal Trade Commission about their $1.1 billion deal....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login